share_log

Exicure | 8-K: Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure | 8-K: Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure | 8-K：Exicure, Inc. 公佈2024年第二季度財務業績
美股SEC公告 ·  2024/08/13 13:24

Moomoo AI 已提取核心訊息

Exicure reported Q2 2024 financial results with cash and cash equivalents of $0.5M as of June 30, 2024, down from $0.8M at year-end 2023. The company's G&A expenses decreased to $1.2M from $5.6M YoY, while net loss improved to $0.6M compared to $5.8M in Q2 2023. The company generated $0.6M in other income from selling clinical product samples.Following its September 2022 restructuring, which included workforce reduction and suspension of all R&D activities, the company is actively exploring strategic alternatives to maximize stockholder value. Management emphasizes that current cash reserves are insufficient to sustain operations, and substantial additional financing is urgently needed in the very near term.The company's ability to further reduce costs is limited due to previous significant cost-cutting measures. There is no assurance that additional financing will be available or obtainable on acceptable terms, raising serious concerns about the company's ability to continue operations.
Exicure reported Q2 2024 financial results with cash and cash equivalents of $0.5M as of June 30, 2024, down from $0.8M at year-end 2023. The company's G&A expenses decreased to $1.2M from $5.6M YoY, while net loss improved to $0.6M compared to $5.8M in Q2 2023. The company generated $0.6M in other income from selling clinical product samples.Following its September 2022 restructuring, which included workforce reduction and suspension of all R&D activities, the company is actively exploring strategic alternatives to maximize stockholder value. Management emphasizes that current cash reserves are insufficient to sustain operations, and substantial additional financing is urgently needed in the very near term.The company's ability to further reduce costs is limited due to previous significant cost-cutting measures. There is no assurance that additional financing will be available or obtainable on acceptable terms, raising serious concerns about the company's ability to continue operations.
Exicure於2024年第二季度發佈財務報告，截至2024年6月30日，現金及現金等價物爲50萬美元，低於2023年年末的80萬美元。公司的管理費用同比減少至120萬美元，較去年同期的560萬美元大幅下降，而淨虧損改善至60萬美元，相比2023年第二季度的580萬美元有所減少。該公司通過銷售臨牀產品樣本產生了60萬美元的其他收入。在2022年9月進行的重組後，包括裁員和暫停所有研發活動，公司正積極探索戰略選擇，以最大化股東價值。管理層強調，當前的現金儲備不足以維持運營，迫切需要大量額外融資。由於之前採取了顯著的減成本措施，公司進一步降低成本的能力有限。沒有保證額外融資將可獲得或在可接受的條款下獲得，這引發了對公司持續運營能力的嚴重擔憂。
Exicure於2024年第二季度發佈財務報告，截至2024年6月30日，現金及現金等價物爲50萬美元，低於2023年年末的80萬美元。公司的管理費用同比減少至120萬美元，較去年同期的560萬美元大幅下降，而淨虧損改善至60萬美元，相比2023年第二季度的580萬美元有所減少。該公司通過銷售臨牀產品樣本產生了60萬美元的其他收入。在2022年9月進行的重組後，包括裁員和暫停所有研發活動，公司正積極探索戰略選擇，以最大化股東價值。管理層強調，當前的現金儲備不足以維持運營，迫切需要大量額外融資。由於之前採取了顯著的減成本措施，公司進一步降低成本的能力有限。沒有保證額外融資將可獲得或在可接受的條款下獲得，這引發了對公司持續運營能力的嚴重擔憂。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！